feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / FDA Approves Oral Wegovy: Game Changer for Dieters?

FDA Approves Oral Wegovy: Game Changer for Dieters?

23 Dec, 2025

•

Summary

  • FDA approved the first oral version of the popular Wegovy weight loss drug.
  • The pill requires strict adherence for maximum weight loss results.
  • Oral GLP-1 drugs may offer less weight loss than injections.
FDA Approves Oral Wegovy: Game Changer for Dieters?

The Food and Drug Administration has granted approval for an oral version of Wegovy, Novo Nordisk's widely recognized weight loss medication. This marks the introduction of the first pill form for a GLP-1 drug specifically for weight management, with a similar option from Eli Lilly anticipated soon. These GLP-1 compounds, initially for diabetes, have surged in popularity due to their effectiveness in facilitating significant weight loss.

Dr. Christopher McGowan highlighted the pill's potential to broaden treatment options, noting that pills are often more psychologically acceptable and easier to integrate into daily routines than injections. While the exact list price is unreleased, it's expected to be lower than injectable versions. Clinical trials indicate that the highest dose of the Wegovy pill led to an average weight loss of 16.6% over 64 weeks, comparable to its injectable form.

However, maintaining strict adherence to the daily regimen—taking the pill first thing in the morning on an empty stomach with water—is critical, as deviations resulted in less weight loss in trials. Gastrointestinal side effects, such as nausea and vomiting, are common, potentially intensified by the pill's immediate release. Experts are still evaluating its 'real-world performance' regarding patient compliance and long-term efficacy.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The FDA approved the first oral version of Wegovy, a GLP-1 drug for weight loss, to be taken daily.
Clinical trials showed the highest dose of the Wegovy pill led to an average 16.6% body weight loss over 64 weeks.
Common side effects include nausea and vomiting, which may feel more intense due to the pill's immediate release.

Read more news on

Healthside-arrow
trending

Islamabad suicide blast kills 31

trending

Ronaldo trains with Al Nassr

trending

India A vs Namibia live

trending

Vaibhav Suryavanshi scores 175

trending

VTU adopts Artificial Super Intelligence

trending

Riyan Parag scores fifty

trending

T20 World Cup opening ceremony

trending

Tiigers Kolkata reach ISPL final

trending

Al Ettifaq favored vs Damac

You may also like

Hims & Hers Launches Wegovy Competitor at $49

1 day ago • 9 reads

article image

Novo Nordisk Launches Oral Ozempic in Q2

5 Feb • 11 reads

article image

Knock-off Weight Drugs: Deadly Risks Exposed

30 Jan • 79 reads

article image

Blindness, Ruptured Colon: Lawsuits Target Ozempic

28 Jan • 81 reads

article image

Novo, Lilly clash in $700M ad war

28 Jan • 78 reads

article image